Kazia Therapeutics Annual Report 2021

30 Kazia Therapeutics Limited 0 Annual Report 2021 Name: Kate Hill Title: Company Secretary Agreement commenced: 9 September 2016 Term of agreement: Part-time contractor Details: Base remuneration is based on time worked. Daily rate to be reviewed annually by the Remuneration and Nomination Committee, with a monthly rate of $11,900 for a two-day week, applied from 1 January 2021. The contract is open ended. Kate’s appointment with the consolidated entity may be terminated with the consolidated entity giving 60 days’ notice or by Kate giving 60 days’ notice. Key management personnel have no entitlement to termination payments in the event of removal for misconduct. Share-based compensation Issue of options The terms and conditions of each grant of options over ordinary shares granted as remuneration to Directors or other Key Management Personnel in this financial year or future financial years are set out below. The options issued on 9 November 2020 were to James Garner (800,000 options with a fair value at grant date of $402,000), Iain Ross (400,000 options with a fair value at grant date of $165,300), Bryce Carmine (400,000 options with a fair value at grant date of $165,300) and Steven Coffey (400,000 options with a fair value at grant date of $165,300). The options issued on 4 January 2021 were to Kate Hill (50,000 options, with a fair value at grant date of $29,929) and Gabrielle Heaton (50,000 options, with a fair value at grant date of $29,929). Service conditions are that any unvested options are forfeit on cessation of employment. There are no performance conditions, consistent with the Company’s Employee Share Option Plan rules, as reapproved by shareholders on 6 November 2020. Grant date No of options Vesting date Expiry date Exercise price $ Fair value at grant date $ 09/11/2020 200,000 13/01/2021 13/01/2025 $0.881 $0.450 09/11/2020 200,000 13/01/2022 13/01/2025 $0.881 $0.490 09/11/2020 200,000 13/01/2023 13/01/2025 $0.881 $0.520 09/11/2020 200,000 13/01/2024 13/01/2025 $0.881 $0.550 09/11/2020 300,000 01/01/2021 09/11/2024 $1.132 $0.379 09/11/2020 300,000 01/07/2021 09/11/2024 $1.132 $0.403 09/11/2020 300,000 01/01/2022 09/11/2024 $1.132 $0.425 09/11/2020 300,000 01/07/2022 09/11/2024 $1.132 $0.446 04/01/2021 25,000 04/01/2022 04/01/2025 $1.690 $0.520 04/01/2021 25,000 04/01/2023 04/01/2025 $1.690 $0.576 04/01/2021 25,000 04/01/2024 04/01/2025 $1.690 $0.627 04/01/2021 25,000 04/01/2025 04/01/2025 $1.690 $0.671 2,100,000 Options granted carry no dividend or voting rights. Each option is convertible to one ordinary share upon exercise. During the year, 96,500 options were exercised by Gabrielle Heaton and 245,000 options were exercised by Kate Hill.